

PAH Clinical Scenarios: Advances in Diagnostic Assessment, Guideline Recommended Care, and Emerging Treatments

Clinical Brief #3 – Emerging Treatments

References

Tweet 3 References:

Galkin A, Sitapara R, Clemons B, et al. Inhaled soralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. *Eur Respir J*. 2022;60:2102356.

Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. *N Engl J Med*. 2021;384:1204-1215.

Kaiser N, Tonelli AR. Novel treatment pathways in pulmonary arterial hypertension. *Methodist Debaque Cardiovasc J*. 2021;17:106-114.

Additional References:

Carvalho T. Merck bets on sotatercept in pulmonary arterial hypertension. *Nat Med*. 2022 Nov 17. [Online ahead of print]

ClinicalTrials.gov. Accessed April 12, 2023.

Frantz RP, Benza RL, Channick RN, et al. TORREY, a phase 2 study to evaluate the efficacy and safety of inhaled soralutinib for the treatment of pulmonary arterial hypertension. *Pulm Cir*. 2021;11:20458940211057071.

Galkin A, Sitapara R, Clemons B, et al. Inhaled soralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. *Eur Respir J*. 2022;60:2102356.

Gillies H, Niven R, Dake BT, et al. AV-101, a novel inhaled dry powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study. *ERJ Open Res*. 2022. In press. <https://doi.org/10.1183/23120541.00433-2022>.

Gossamer Bio announces soralutinib meets primary endpoint in phase 2 TORREY study in PAH. December 6, 2022. Accessed January 18, 2023. <https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-announces-soralutinib-meets-primary-endpoint-phase>

Grundy JS, King CD, Adams JW, Cabell CH. Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers. *Pulm Circ*. 2020;10:2045894020922814.

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022;43:3618-3731.

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J*. 2023;61:2200879.

Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. *N Engl J Med*. 2021;384:1204-1215.

Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. *Eur Respir J*. 2023;61:2201347.

PharmaLetter. Sotatercept set to become leading therapy in PAH market, says analyst. November 11, 2022. Accessed January 18, 2023. <https://www.thepharmaletter.com/article/sotatercept-set-to-become-leading-therapy-in-pah-market-says-analyst>

Kaiser N, Tonelli AR. Novel treatment pathways in pulmonary arterial hypertension. *Methodist Debaquey Cardiovasc J*. 2021;17:106-114.

Glossary

BMPR2, bone morphogenetic protein receptor 2

cGMP, cyclic guanosine monophosphate

c-KIT, mast/stem cell growth factor receptor kit

CSF1R, colony-stimulating factor 1 receptor

dyn/sec/cm, dyn second per square centimeter

INH, inhaled

HIMF, hypoxia-induced mitogenic factor

NO, nitric oxide

PAH, pulmonary arterial hypertension

PDGFR, platelet-derived growth factor receptor

PGI2, prostaglandin I2 (ie, prostacyclin)

PVR, pulmonary vascular resistance

RHC, right-heart catheterization

SC, subcutaneous

sGC, soluble guanylate cyclase

SHH, Sonic Hedgehog protein

TGF- β , transforming growth factor beta

TKI, tyrosine kinase inhibitor

w/, with